Bright Minds Biosciences (DRUG) Price & Analysis

Compare

240 Followers

DRUG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.94 - $79.02

Previous Close$40.4

Volume34.65K

Average Volume (3M)46.37K

Market Cap

C$307.43M

Enterprise Value$204.27M

Total Cash (Recent Filing)C$55.68M

Total Debt (Recent Filing)C$166.60K

Price to Earnings (P/E)―

Beta4.21

Next Earnings

Dec 18, 2025

EPS Estimate

-0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding7,083,239

10 Day Avg. Volume64,237

30 Day Avg. Volume46,369

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$82.50

Price Target Upside81.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Market OpportunityAbsence epilepsy accounts for about 10% of all epilepsy patients and is most common in children, presenting a significant market opportunity.

Treatment PotentialLead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class for the treatment of certain refractory seizure disorders.

Trial ProgressRecruitment remains on track for the Phase II trial of BMB-101 in absence epilepsy and DEE, with data expected to show activity supporting further development.

Bears Say

Competitive PressureThe data have a high bar due to the potent anti-seizure activity shown by competitive 5-HT2C agonists in certain DEE populations.

Data ExpectationsThe unique Gq-biased 5-HT2C mechanism and robust preclinical and Phase 1 dataset of BMB-101 distinguish it from peers, setting high expectations for its therapeutic profile.

Bright Minds Biosciences News

Psychedelic: atai Life Sciences, Cybin report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

5d ago

ATAI

CYBN

Bright Minds Biosciences: Advancing Breakthrough Epilepsy Treatment with BMB-101 and Strong Financial Position

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

2h ago

DRUG

Bright Minds Biosciences Reports Q3 2025 Financial Results

Bright Minds Biosciences ( ($TSE:DRUG) ) has shared an announcement. Bright Minds Biosciences Inc. has released its Condensed...

4d ago

DRUG

Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

ATAI

CMND

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’...

2M ago

DRUG

Bright Minds Biosciences to Present at 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an announcement. Bright Minds Biosciences announced that its CEO and...

3M ago

DRUG

Bright Minds Biosciences’ BMB-101: A Promising Breakthrough in Treatment-Resistant Epilepsy

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences...

3M ago

DRUG

Bright Minds Biosciences: Buy Rating Issued on Promising Potential of BMB-101 for Absence Seizures

TD Cowen analyst Joseph Thome has maintained their bullish stance on DRUG stock, giving a Buy rating on...

3M ago

DRUG

Bright Minds Biosciences Hosts Virtual R&D Day on Absence Epilepsy

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced the featured speakers for...

3M ago

DRUG

Bright Minds announces speakers for Absence epilepsy R&D Day

Bright Minds (DRUG) Biosciences announced the featured speakers for its virtual R&D Day on Tuesday, May 20, 2025,...

3M ago

DRUG

VA secretary wants to find answers on psychedelics therapies, Politico says

Veterans Affairs Secretary Doug Collins wants to find out whether psychedelic drugs can successfully treat veterans with PTSD...

3M ago

ATAI

CYBN

Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

TMO

ATAI

Bright Minds Biosciences Reports Promising Results for Epilepsy Treatment

An update from Bright Minds Biosciences ( ($TSE:DRUG) ) is now available. Bright Minds Biosciences announced positive results...

3M ago

DRUG

Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

BRO

CAT

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was $0.94 and its highest was $79.02 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$307.43M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Dec 18, 2025 which is in 121 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.536 earnings per share for the quarter, beating the consensus estimate of -$0.575 by $0.039.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.62.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,083,239 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -$0.536 in its last earnings report, beating expectations of -$0.575. Following the earnings report the stock price went up 4.92%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in DRUG

Bright Minds Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-30.79%

Trailing 12-Months

Asset Growth

736.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Bright Minds Biosciences (DRUG) Earnings & Revenues

Historic Earnings Reports

DRUG Stock 12 Month Forecast

Average Price Target

$82.50

▲(81.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","85":"$85","21.25":"$21.3","42.5":"$42.5","63.75":"$63.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84.9999999290624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.49786832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$82.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.9999999332352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,21.25,42.5,63.75,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.63,37.581538456081724,41.53307691216345,45.48461536824517,49.436153824326894,53.387692280408615,57.339230736490336,61.290769192572064,65.24230764865379,69.19384610473551,73.14538456081723,77.09692301689896,81.04846147298068,{"y":84.9999999290624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.63,37.389066793846155,41.14813358769231,44.90720038153846,48.66626717538462,52.42533396923076,56.18440076307692,59.943467556923075,63.70253435076923,67.46160114461537,71.22066793846153,74.97973473230769,78.73880152615385,{"y":82.49786832,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.63,37.196923071787324,40.763846143574646,44.33076921536197,47.8976922871493,51.46461535893661,55.03153843072394,58.59846150251126,62.165384574298585,65.7323076460859,69.29923071787323,72.86615378966056,76.43307686144789,{"y":79.9999999332352,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.15,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.06,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.1,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >